Human IL-35 R / gp130 & IL12Rb2 Protein, His Tag (MALS verified)
分子別名(Synonym)
IL-35 R, gp130 & IL12Rb2, CD130 & IL12Rb2, IL-6RB & IL12Rb2, gp130 & IL12Rb2
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-35 R, His Tag (ILR-H52H8) is expressed from human 293 cells (HEK293). It contains AA Glu 23 - Glu 619 & Lys 24 - Asn 622 (Accession # P40189-1(gp130) & Q99665-1(IL12Rb2)).
Predicted N-terminus: Glu 23 & Lys 24
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 73.1 kDa & 71.5 kDa. The protein migrates as 95-130 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景介紹
白細(xì)胞介素35(IL-35)是近期從IL-12家族中發(fā)現(xiàn)的一種抗炎性細(xì)胞因子。作為IL-12家族成員,該細(xì)胞因子由多種調(diào)節(jié)性淋巴細(xì)胞產(chǎn)生,在免疫抑制中發(fā)揮重要作用。IL-35可通過限制早期T細(xì)胞增殖,阻斷Th1和Th17細(xì)胞的分化。其異二聚體結(jié)構(gòu)包含p35和Ebi3兩個亞基——這兩個亞基同樣存在于IL-12和IL-27中。因此,IL-35被公認(rèn)為具有強(qiáng)大免疫抑制潛力的明確有效的免疫抑制劑。
關(guān)鍵字: IL-35 R;IL-35 R蛋白;IL-35 R重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。